Genetic testing

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

Retrieved on: 
Friday, December 2, 2022

SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies.

Key Points: 
  • SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies.
  • Data was collected from more than 17,000 patients through Invitae Corporation's Behind the Seizure Program, of which Neurocrine Biosciences is a sponsor.
  • These data (Poster #2.099: Demographic and Clinical Characteristics of Pediatric Patients with SCN8A-related Epilepsies: Results from a No-Charge Epilepsy Gene Panel) will be shared at the AES 2022 Annual Meeting in Nashville, Tennessee, December 26, 2022.
  • Data analysis demonstrated that 36 (0.2%) of the patients had an SCN8A variant that was classified as pathogenic (P) or likely pathogenic (LP).

Worldwide Paternity & Relationship Testing Services Industry to 2027: by Application and Product - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

Maternity testing, Grandparent testing.

Key Points: 
  • Maternity testing, Grandparent testing.
  • Sibling testing.
  • Infidelity testing?
  • Direct to Consumer genetic testing is driving the need for legally recognized relationship testing.

Shore Quality Partners Teams with Genomind to Help Prevent Adverse Prescription Drug Events

Retrieved on: 
Thursday, December 1, 2022

This will allow SQP to assess current patients treatment regimens and stratify individuals based on medication and genetic interaction risk.

Key Points: 
  • This will allow SQP to assess current patients treatment regimens and stratify individuals based on medication and genetic interaction risk.
  • Ultimately, Genomind will provide members identified as high-risk with pharmacogenetic (PGx) testing, and SQP healthcare providers with decision support tools and consultative services for precision medication management.
  • Additionally, the Genomind PGx panel includes gene targets of historically underserved populations which furthers their goal of addressing healthcare inequities.
  • Were thrilled to join SQP in helping to improve care management for patients who are at high risk for these adverse drug events, said Dr. Krause.

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference

Retrieved on: 
Thursday, December 1, 2022

About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. Rhythm’s precision medicine, setmelanotide, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). The European Commission (EC) and Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity and is leveraging the Rhythm Engine and the largest known obesity DNA database -- now with approximately 45,000 sequencing samples -- to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. Rhythm’s headquarters is in Boston, MA.

Key Points: 
  • A replay of the webcast will be available on the Rhythm website for 30 days following the presentation.
  • 2022 Rhythm Pharmaceuticals, Inc. All Rights Reserved.
  • Inthe United StatesandEurope, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

China Genetic Testing Market Analysis Report 2022: An $8 Billion Market by 2027 Featuring BGI, Berry Genomics, Daan Gene, WuXi NextCODE, Annoroad Gene Technology, & WuXi PharmaTech - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

The "China Genetic Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Genetic Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The China genetic testing market size reached US$ 3.1 Billion in 2021.
  • What is the breakup of the China genetic testing market based on the testing sample?
  • The report has also examined the competitive landscape of the China genetic testing market.

Global Direct-To-Consumer Genetic Testing Market to Grow by $1.26 Billion During 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

The "Global Direct-To-Consumer Genetic Testing Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Direct-To-Consumer Genetic Testing Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The direct-to-consumer genetic testing market is poised to grow by $1.26 bn during 2022-2026, accelerating at a CAGR of 13.36% during the forecast period.
  • This report on the direct-to-consumer genetic testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The market is driven by growing adoption of direct-to-consumer genetic testing in early disease diagnosis, rising disposable income, and increasing regulatory approvals of direct-to-consumer genetic testing kits.

Volpara Health software used in largest image quality evaluation to date

Retrieved on: 
Wednesday, November 30, 2022

CHICAGO, Nov. 30, 2022 /PRNewswire/ -- At the 2022 Radiological Society of North America (RSNA) Annual Meeting, Peter R. Eby, MD, of Virginia Mason Medical Center presented the results of the largest mammographic image quality evaluation to date, titled "Reduction in technical repeat and recall rate after implementation of artificial intelligence driven quality improvement software."

Key Points: 
  • Volpara Analytics uses artificial intelligence (AI) to automatically and objectively measure the image quality of every mammogram image taken.
  • These improvements in objectively measured image quality indicators corresponded with technical repeats and recall rates decreasing from 0.77% ("baseline") to 0.17% ("current").
  • "Through the objective analysis of images, Volpara Analytics can help facilities improve image quality and reduce technical repeats and recalls."
  • Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose.

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

Retrieved on: 
Wednesday, November 30, 2022

Following the inclusion of Prenetics, there will be a total of 17 HK-headquartered companies included in this Hong Kong index.

Key Points: 
  • Following the inclusion of Prenetics, there will be a total of 17 HK-headquartered companies included in this Hong Kong index.
  • According to MSCI, the entire MSCI Global Micro Cap index includes a total of 299 constituents in 22 developed markets (with Hong Kong included).
  • It is widely recognised as a benchmark for global institutional investors to optimise their investment portfolios especially passive index funds.
  • In addition, Prenetics' inclusion in the MSCI Global Micro Cap Index (Hong Kong) represents a key milestone and reflects the confidence of stakeholders in the Company's long term growth strategy.

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

Retrieved on: 
Wednesday, November 30, 2022

The Company plans to fund the repurchase program using existing cash and cash equivalents or future cash flow.

Key Points: 
  • The Company plans to fund the repurchase program using existing cash and cash equivalents or future cash flow.
  • Following the inclusion of Prenetics, there will be a total of 17 HK-headquartered companies included in this Hong Kong index.Accordingto MSCI, the entire MSCI Global Micro Cap index includesa total of 299 constituents in 22 developed markets (with Hong Kong included).
  • It is widely recognised as a benchmark for global institutional investors to optimise their investment portfolios especially passive index funds.
  • In addition, Prenetics inclusion in the MSCI Global Micro Cap Index (Hong Kong) represents a key milestone and reflects the confidence of stakeholders in the Companys long term growth strategy.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Retrieved on: 
Tuesday, November 29, 2022

SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc ., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.

Key Points: 
  • SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc ., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.
  • The study looked at prospective long-term outcome data with EndoPredict for women with early-stage breast cancer.
  • Among the Myriad products highlighted in the companys SABCS exhibit are:
    MyRisk with RiskScore , Myriads market-leading hereditary cancer test that offers the first polygenic breast cancer risk assessment for women of all ancestries.
  • RiskScore delivers a personalized 5-year and lifetime risk for developing breast cancer for women who qualify for MyRisk.